ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 87 filers reported holding ONCOMED PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $473,000 | +5.1% | 51,311 | -12.0% | 0.00% | – |
| Q4 2016 | $450,000 | -31.3% | 58,329 | +1.8% | 0.00% | – |
| Q3 2016 | $655,000 | -4.8% | 57,286 | +2.5% | 0.00% | -100.0% |
| Q2 2016 | $688,000 | +26.9% | 55,897 | +4.3% | 0.00% | – |
| Q1 2016 | $542,000 | -73.4% | 53,603 | -40.7% | 0.00% | -100.0% |
| Q4 2015 | $2,038,000 | +35.9% | 90,439 | 0.0% | 0.00% | +100.0% |
| Q3 2015 | $1,500,000 | -27.9% | 90,439 | -2.2% | 0.00% | 0.0% |
| Q2 2015 | $2,080,000 | +0.9% | 92,447 | +15.6% | 0.00% | 0.0% |
| Q1 2015 | $2,061,000 | +30.3% | 79,941 | +10.0% | 0.00% | 0.0% |
| Q4 2014 | $1,582,000 | +28.1% | 72,701 | +11.5% | 0.00% | 0.0% |
| Q3 2014 | $1,235,000 | -26.7% | 65,228 | -9.7% | 0.00% | 0.0% |
| Q2 2014 | $1,684,000 | +294.4% | 72,261 | +469.9% | 0.00% | – |
| Q1 2014 | $427,000 | +14.2% | 12,680 | 0.0% | 0.00% | – |
| Q4 2013 | $374,000 | +142.9% | 12,680 | +25.8% | 0.00% | – |
| Q3 2013 | $154,000 | – | 10,080 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |